{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:18:47Z","timestamp":1768735127071,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:00:00Z","timestamp":1437091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Intramural Research Program of the National Institute of Allergy and Infectious Diseases"},{"name":"National Council for Scientific Research"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.tranon.2015.07.001","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T18:52:12Z","timestamp":1446058332000},"page":"347-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phospho-MEK1\/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2\/LF)"],"prefix":"10.1016","volume":"8","author":[{"given":"Amira","family":"Bekdash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Timsah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Kassab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba","family":"El-Hajj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Bazerbachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Leppla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur E.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph J.","family":"Abi-Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2015.07.001_bb0005","series-title":"Cancer Facts and Figures","author":"American Cancer Society","year":"2012"},{"key":"10.1016\/j.tranon.2015.07.001_bb0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF03165122","article-title":"The myelodysplastic syndromes: morphology, risk assessment, and clinical management","volume":"2","author":"Bennett","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tranon.2015.07.001_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2015.07.001_bb0020","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2015.07.001_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1083\/jcb.200211018","article-title":"Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin dependent process","volume":"160","author":"Abrami","year":"2003","journal-title":"J Cell Biol"},{"key":"10.1016\/j.tranon.2015.07.001_bb0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1083\/jcb.200507067","article-title":"Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis","volume":"172","author":"Abrami","year":"2006","journal-title":"J Cell Biol"},{"key":"10.1016\/j.tranon.2015.07.001_bb0035","doi-asserted-by":"crossref","first-page":"9802","DOI":"10.1073\/pnas.0604000103","article-title":"A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformation","volume":"103","author":"Melnyk","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2015.07.001_bb0040","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","article-title":"Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor","volume":"280","author":"Duesbery","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.tranon.2015.07.001_bb0045","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1074\/jbc.M211262200","article-title":"Anthrax lethal factor proteolysis and inactivation of MAPK kinase","volume":"278","author":"Chopra","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tranon.2015.07.001_bb0050","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1073\/pnas.052707699","article-title":"Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase","volume":"99","author":"Koo","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2015.07.001_bb0055","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1535-7163.MCT-05-0145","article-title":"Braf status and mitogen-activated protein\/extracellular signal\u2013regulated kinase kinase 1\/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin","volume":"4","author":"Abi-Habib","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.tranon.2015.07.001_bb0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nature12510","article-title":"Key tissue targets responsible for anthrax-toxin-induced lethality","volume":"501","author":"Liu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2015.07.001_bb0065","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/sj.leu.2403250","article-title":"CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review","volume":"18","author":"B\u00e9n\u00e9","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2015.07.001_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.20337","article-title":"High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis","volume":"79","author":"Graf","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tranon.2015.07.001_bb0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s000180050497","article-title":"The plasminogen activation system in tumor growth, invasion, and metastasis","volume":"57","author":"Andreasen","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.tranon.2015.07.001_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1699-0463.1999.tb01534.x","article-title":"Cancer invasion and tissue remodeling\u2014cooperation of protease systems and cell types","volume":"107","author":"Dano","year":"1999","journal-title":"APMIS"},{"key":"10.1016\/j.tranon.2015.07.001_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0145-2126(02)00077-2","article-title":"The diphtheria toxin\/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells","volume":"27","author":"Ramage","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.tranon.2015.07.001_bb0090","doi-asserted-by":"crossref","first-page":"17976","DOI":"10.1074\/jbc.M011085200","article-title":"Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin","volume":"276","author":"Liu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tranon.2015.07.001_bb0095","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1073\/pnas.0236849100","article-title":"Potent antitumor activity of a urokinase-activated engineered anthrax toxin","volume":"100","author":"Liu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2015.07.001_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1593\/tlo.12313","article-title":"Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal\u2013regulated kinase 1\/2 activity","volume":"6","author":"Kassab","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.tranon.2015.07.001_bb0105","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2004-01-0339","article-title":"A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts","volume":"104","author":"Abi-Habib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2015.07.001_bb0110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.jim.7000239","article-title":"Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis","volume":"28","author":"Ramirez","year":"2002","journal-title":"J Ind Microbiol Biotechnol"},{"key":"10.1016\/j.tranon.2015.07.001_bb0115","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.leukres.2013.08.007","article-title":"Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells","volume":"37","author":"Tanios","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.tranon.2015.07.001_bb0120","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1158\/1078-0432.CCR-06-2019","article-title":"Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice","volume":"12","author":"Abi-Habib","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2015.07.001_bb0125","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1055\/s-0038-1650701","article-title":"Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells","volume":"76","author":"Jardi","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tranon.2015.07.001_bb0130","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1535-7163.MCT-06-0315","article-title":"A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types","volume":"5","author":"Abi-Habib","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.tranon.2015.07.001_bb0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/djk065","article-title":"A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease","volume":"99","author":"Williams","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.tranon.2015.07.001_bb0140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/CAD.0b013e3280bad82d","article-title":"Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity","volume":"18","author":"Singh","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tranon.2015.07.001_bb0145","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.eururo.2010.11.024","article-title":"Safety and efficacy of intraprostatic injection of PRX302, a PSA-activated pore-forming toxin, for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"59","author":"Denmeade","year":"2011","journal-title":"Eur Urol"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523315000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523315000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:31:05Z","timestamp":1761834665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523315000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1936523315000571"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2015.07.001","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phospho-MEK1\/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2\/LF)","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2015.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}